ClinX Names Jason Cunio, former CFO of TandemSeven as Chief Financial Officer

ClinX is pleased to announce the appointment of former TandemSeven CFO, Jason Cunio, as Chief Financial Officer for ClinX, LLC (Umbrella company of ClinEdge, BTC Network & GuideStar Research). In this role, Mr. Cunio will have full oversight and responsibility for leading ClinX companies’ financial operations on a global services platform. He will also serve on the company’s leadership team.

Mr. Cunio has two decades of financial and operational expertise, which includes leading and supporting growth at market leading technology companies. Mr. Cunio has been responsible for formulating strategic financial plans, leading financial operations and supporting successful business development activities including acquisitions and mergers and an IPO.

“It’s the optimal time to be joining ClinX, a forward-thinking company that is experiencing tremendous growth revolutionizing clinical trial service delivery models,” said Mr. Cunio. “It’s very exciting to be a part of the leadership team of an organization that is an innovator at the forefront of the industry. I’m committed to boosting the company’s financial profile in the role.”

“Our company is approaching the end of 2019 amidst exponential growth and a clear vision to be a leader in clinical trial service delivery structures,” said Christian Burns, Co-Founder of ClinX and President of ClinEdge. “Jason brings a deep breadth of financial leadership to our growing operations and will be a key addition to our management team.”

Al Peters, ClinX Co-Founder and President of BTC Network added, “Jason is a unique fit based on his prior experience with technology enabled service. He will assist with our prioritization of internal growth initiatives and add to our continued efforts around improving operational efficiencies, maximizing automation, and ability to produce important analytics. As we continue to execute on our longer-term strategy, Jason will help us better understand market opportunities and make crucial decisions on how to adapt."

Prior to joining ClinX, Mr. Cunio has led an accomplished career, most recently as Assistant Vice President at Genpact where he focused on post-merger integration and supported strategic financial initiatives for the Digital business. Jason previously held the CFO position at TandemSeven, Inc., where he was integral in the acquisition by Genpact, Controller at Revenue Solutions, Inc; and other positions at FirstWind, VistaPrint and Deloitte.

About ClinX:

ClinEdge, BTC Network, and GuideStar Research are the affiliated companies that comprise ClinX. Together, the companies provide a full range of clinical and outsourced business services to clinical research institutions, pharmaceutical companies, and CROs. The companies include: two global networks of research clinics; consulting and financial management services; and a patient recruitment and retention division. With extensive experience over 300 different medical indications representing all therapeutic areas, the three companies have helped clients successfully conduct thousands of clinical studies over the last several years. Each of the companies’ units work together to streamline clinical research operations, minimize enrollment timelines, and overall, help the clinical research industry thrive.


ClinEdge Announced as a Finalist in Excellence in Rare Disease Drug Development

QUINCY, MA – February 27, 2019 – ClinEdge has been named a finalist in the Excellence in Rare Disease Drug Development category in the CARE Awards, which recognizes companies that dedicate themselves to rare disease work across the global clinical research enterprise.

The 2019 winners will be announced at a ceremony on Thursday, May 2, 2019 at the Hyatt Regency in Boston, MA, where distinguished leaders in the biopharmaceutical, CRO, and diagnostic industries gather from all corners of the globe.

The ClinEdge Rare Disease program utilizes defined methods to compassionately engage, partner, and empower rare disease patients and their families. Our global strategies improve the clinical trial process by using the voice of the patient to build and support clinical trial programs, using their own journey and story to increase patient engagement and retention. To be nominated in a category that recognizes excellence in rare disease speaks to the innovation and heart that supports the program’s mission.

The CARE Awards 2019 features 11 categories, which showcase significant accomplishments and highlight innovation across the industry – from rare disease drug development and patient-centricity in trials and research, to product and technological development, clinical results and collaborative efforts between individuals, departments, or companies. Entries are judged independently by a panel of experts from all core sectors of the clinical R&D industry.

“It is truly an honor to be nominated for a CARE Award in 2019,” says ClinEdge President, Christian Burns. “Advancing the care, accessibility, and awareness of clinical trials for rare disease communities has been one of our key company missions since inception. It is humbling to see our rare disease program and its affiliated teams be recognized for their outstanding achievements, and to know that recognition stems from the role we have played in making a positive impact on rare disease research.”

You can view the full list of finalists here: https://pharmaintelligence.informa.com/events/awards/care-awards-2019/shortlist

 

About Informa Pharma Intelligence

Informa Pharma Intelligence powers a full suite of analysis products – Datamonitor Healthcare, Sitetrove, Trialtrove, Pharmaprojects, Medtrack, Biomedtracker, Scrip, Pink Sheet and In Vivo – to deliver the data needed by the pharmaceutical and biomedical industry to make decisions and create real-world opportunities for growth.

With more than 500 analysts keeping their fingers on the pulse of the industry, no key disease, clinical trial, drug approval or R&D project isn’t covered through the breadth and depth of data available to customers. For more information visit pharmaintelligence.informa.com.

 

About ClinX

ClinX, the parent company of ClinEdgeBTC Network, and GuideStar Research, is a global service solutions provider for research sites, patients, and healthcare organizations involved in managing, conducting, and participating in clinical research. The strength of our unique companies offers a focused vision in building platforms and ecosystems that drive innovation for our clientele and patients.

ClinEdge combines patient recruitment and business development services under one umbrella as a means to empower patients and stakeholders to advance clinical trials as a healthcare option. Our Rare Disease program specifically addresses the unique needs of rare disease patients, and emphasizes the importance of collaborating with patients for ideal clinical outcomes.


ClinEdge and BTC Network Announce Collaboration with GuideStar Research

 

BOSTON--(BUSINESS WIRE)--ClinX, the holding company to ClinEdge and BTC Network, has acquired GuideStar Research. “Guidestar will continue to operate under its own name as a separate business unit with its existing infrastructure, which is great,” said Al Peters, President of BTC Network and Managing Director of ClinX. “ClinX will support Guidestar in its overall service excellence strategy by broadening product lines and adding new skills.”

This new partnership allows ClinX to continue to create a new research site services category dedicated to streamlining operations at the institutional level. The industry is witnessing the first multi-service company that brings a wide spectrum of services to those involved in conducting clinical trials, from hospitals and universities to private practice and dedicated research sites.

ClinEdge President & Managing Director of ClinX, Christian Burns is thrilled to announce the new venture. “Bringing together ClinEdge and BTC Network’s significant experience supporting private practices, health systems and research sites, and GuideStar Research’s unprecedented experience providing services to hospitals, academic organizations and universities was a no-brainer,” comments Burns. “Together with each company’s proven success, we will help deliver the most comprehensive and dynamic support system for research institutions of all types across the industry.”

Ed Michael Reggie, GuideStar Research’s Chairman agrees. “When our teams began exploring collaborative efforts, it quickly became clear that we had an opportunity to combine the top talent in the industry to create an unparalleled clinical research service model,” explained Reggie. “The combined strengths of these three companies is incredibly unique and powerful.”

Best practices from ClinEdge, BTC Network and now GuideStar Research will be incorporated across the organization’s global network of sites and through all of its service offerings. The integrated commercial approach benefits clients with a single comprehensive solution for trial sponsors and research sites focused on operational excellence.

Together as ClinX, the three companies fuse their incredible breadth and depth of services, which include; financial management, coverage analysis, consulting, study cultivation, patient recruitment, research site marketing, staffing, patient travel and more.

About ClinEdge

ClinEdge is a full-service business development, marketing, and patient recruitment firm dedicated to the success of clinical trials. The company’s two divisions, ClinEdge Engage, a leader in patient recruitment and retention, and ClinEdge Network, a network of high-performing investigational facilities across three continents, cultivate and maintain strong relationships with the world’s leading research facilities, pharmaceutical companies and contract research organizations (CROs).

About BTC Network

BTC Network is an organization dedicated to streamlining the entire clinical trial process. BTC’s integrated network of research sites takes advantage of centralized services including pipeline management, financial operations, regulatory assistance, and patient recruitment. BTC works with sites and sponsors alike to make the conduct of clinical trials more efficient and cost-effective.

About GuideStar Research

GuideStar Research works with hospitals, health systems, academic medical centers and physician practices around the country to optimize clinical research programs. From helping to create clinical trial strategies to providing administrative support services, GuideStar Research’s service delivery led by the highest level of expertise is based on operational best practices to ensure clinical research program success.